MET and colorectal carcinoma: In fact, our findings highlight the therapeutic potential of improving the efficacy of c-Met inhibitors by targeting YAP or DPY30, the downstream mediators of the cellular consequences of loss of ABHD5, in patients harbouring CRC with low ABHD5 expression.